
## Ke-Fei Dou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5011903/publications.pdf Version: 2024-02-01



KE-FEI DOU

#	Article	IF	CITATIONS
1	Global Chronic Total Occlusion CrossingÂAlgorithm. Journal of the American College of Cardiology, 2021, 78, 840-853.	2.8	111
2	Myocardial <sup>18</sup> F-FDG Uptake After Exercise-Induced Myocardial Ischemia in Patients with Coronary Artery Disease. Journal of Nuclear Medicine, 2008, 49, 1986-1991.	5.0	59
3	Costs and Benefits Associated With Transradial Versus Transfemoral Percutaneous Coronary Intervention in China. Journal of the American Heart Association, 2016, 5, .	3.7	30
4	Relationship of myocardial hibernation, scar, and angiographic collateral flow in ischemic cardiomyopathy with coronary chronic total occlusion. Journal of Nuclear Cardiology, 2019, 26, 1720-1730.	2.1	25
5	Validation of contemporary risk scores in predicting coronary thrombotic events and major bleeding in patients with acute coronary syndrome after drugâ€eluting stent implantations. Catheterization and Cardiovascular Interventions, 2018, 91, 573-581.	1.7	21
6	Prognostic Value of Quantitative Flow Ratio Based Functional SYNTAX Score in Patients With Left Main or Multivessel Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2020, 13, e009155.	3.9	19
7	Clinical and Angiographic Predictors of Major Side Branch Occlusion after Main Vessel Stenting in Coronary Bifurcation Lesions. Chinese Medical Journal, 2015, 128, 1471-1478.	2.3	12
8	Validation of bifurcation DEFINITION criteria and comparison of stenting strategies in true left main bifurcation lesions. Scientific Reports, 2020, 10, 10461.	3.3	12
9	New Insights Into Long- Versus Short-Term Dual Antiplatelet Therapy Duration in Patients After Stenting for Left Main Coronary Artery Disease: Findings From a Prospective Observational Study. Circulation: Cardiovascular Interventions, 2022, 15, 101161CIRCINTERVENTIONS121011536.	3.9	12
10	The CAMI-score: A Novel Tool derived From CAMI Registry to Predict In-hospital Death among Acute Myocardial Infarction Patients. Scientific Reports, 2018, 8, 9082.	3.3	11
11	Association between smoking and in-hospital mortality in patients with acute myocardial infarction: results from a prospective, multicentre, observational study in China. BMJ Open, 2019, 9, e030252.	1.9	9
12	A novel phenotype with splicing mutation identified in a Chinese family with desminopathy. Chinese Medical Journal, 2019, 132, 127-134.	2.3	9
13	Assessing the association of appropriateness of coronary revascularization and 1-year clinical outcomes for patients with stable coronary artery disease in China. Chinese Medical Journal, 2020, 133, 1-8.	2.3	9
14	Benefit-Risk Profile of DAPT Continuation Beyond 1ÂYear after PCI in Patients with High Thrombotic Risk Features as Endorsed by 2018 ESC/EACTS Myocardial Revascularization Guideline. Cardiovascular Drugs and Therapy, 2020, 34, 663-675.	2.6	9
15	Integrated coronary disease burden and patterns to discriminate vessels benefiting from percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2022, 99, .	1.7	9
16	Dual-time-point myocardial 18F-FDG imaging in the detection of coronary artery disease. BMC Cardiovascular Disorders, 2017, 17, 120.	1.7	8
17	Angiographic characteristics and in-hospital mortality among patients with ST-segment elevation myocardial infarction presenting without typical chest pain. Chinese Medical Journal, 2019, 132, 2286-2291.	2.3	7
18	Percutaneous Coronary Intervention Complexity and Risk of Adverse Events in relation to High Bleeding Risk among Patients Receiving Drug-Eluting Stents: Insights from a Large Single-Center Cohort Study. Journal of Interventional Cardiology, 2020, 2020, 1-10.	1.2	7

Ke-Fei Dou

#	Article	IF	CITATIONS
19	Personalized Early-Warning Signals during Progression of Human Coronary Atherosclerosis by Landscape Dynamic Network Biomarker. Genes, 2020, 11, 676.	2.4	7
20	How Do Lipoprotein(a) Concentrations Affect Clinical Outcomes for Patients With Stable Coronary Artery Disease Who Underwent Different Dual Antiplatelet Therapy After Percutaneous Coronary Intervention?. Journal of the American Heart Association, 2022, 11, e023578.	3.7	6
21	Prognostic Implications of Prestent Pullback Pressure Gradient and Poststent Quantitative Flow Ratio in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American Heart Association, 2022, 11, .	3.7	6
22	Risk/Benefit Tradeoff of Prolonging Dual Antiplatelet Therapy More Than 12 Months in TWILIGHT-Like High-Risk Patients After Complex Percutaneous Coronary Intervention. American Journal of Cardiology, 2020, 133, 61-70.	1.6	5
23	Prognostic significance of occlusion length in recanalized chronic total occlusion lesion: a retrospective cohort study with 5-year follow-up. BMJ Open, 2020, 10, e038302.	1.9	5
24	Contribution of ESC DAPT guideline-endorsed high thrombotic risk features to long-term clinical outcomes among patients with and without high bleeding risk after PCI. BMC Cardiovascular Disorders, 2020, 20, 313.	1.7	5
25	Association of circulating proprotein convertase subtilisin/kexin type 9 concentration, prothrombin time and cardiovascular outcomes: a prospective cohort study. Thrombosis Journal, 2021, 19, 90.	2.1	5
26	Clinical and angiographic characteristics of premenopausal women with coronary artery disease. Chinese Medical Journal, 2008, 121, 2392-6.	2.3	5
27	Benefit and Risk of Prolonged Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Elevated Lipoprotein(a) Concentrations. Frontiers in Cardiovascular Medicine, 2021, 8, 807925.	2.4	5
28	Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCI. Platelets, 2021, 32, 533-541.	2.3	4
29	Prognostic and Practical Validation of ESC/EACTS High Ischemic Risk Definition on Long-Term Thrombotic and Bleeding Events in Contemporary PCI Patients. Journal of Atherosclerosis and Thrombosis, 2022, 29, 502-526.	2.0	4
30	Clinical significance of diabetes on symptom and patient delay among patients with acute myocardial infarction-an analysis from China Acute Myocardial Infarction (CAMI) registry. Journal of Geriatric Cardiology, 2019, 16, 395-400.	0.2	4
31	Clinical characteristics of early and late drug-eluting stent in-stent restenosis and mid-term prognosis after repeated percutaneous coronary intervention. Chinese Medical Journal, 2020, 133, 2674-2681.	2.3	3
32	Predictors for adverse outcomes of patients with recanalized chronic total occlusion lesion. European Journal of Clinical Investigation, 2021, 51, e13368.	3.4	3
33	Early radial artery occlusion following the use of a transradial <scp>7â€French</scp> sheath for complex coronary interventions in Chinese patients. Catheterization and Cardiovascular Interventions, 2021, 97, 1063-1071.	1.7	3
34	Association of symptom status, myocardial viability, and clinical/anatomic risk on longâ€ŧerm outcomes after chronic total occlusion percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2021, 97, 996-1008.	1.7	3
35	Establishing the optimal duration of DAPT following PCI in highâ€risk TWILIGHT â€like patients with acute coronary syndrome. Catheterization and Cardiovascular Interventions, 2021, , .	1.7	3
36	Optimal Strategy for Antiplatelet Therapy After Coronary Drug-Eluting Stent Implantation in High-Risk "TWILIGHT-like―Patients With Diabetes Mellitus. Frontiers in Cardiovascular Medicine, 2020, 7, 586491.	2.4	3

Ke-Fei Dou

#	Article	IF	CITATIONS
37	Invasive versus conservative strategy in consecutive patients aged 80 years or older with non-ST-segment elevation myocardial infarction: a retrospective study in China. Journal of Geriatric Cardiology, 2019, 16, 741-748.	0.2	3
38	Intraâ€aortic balloon pump in cardiogenic shock: A propensity score matching analysis. Catheterization and Cardiovascular Interventions, 2022, 99, 1456-1464.	1.7	3
39	Impact of Lipoprotein(a) concentrations on long-term cardiovascular outcomes in patients undergoing percutaneous coronary intervention: A large cohort study. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1670-1680.	2.6	3
40	A retrospective study of an invasive versus conservative strategy in patients aged ≥80 years with acute ST-segment elevation myocardial infarction. Journal of International Medical Research, 2019, 47, 4431-4441.	1.0	2
41	Fuster-BEWAT score versus cardiovascular health score to predict subclinical target organ damage: Insights from a large-scale Asian population. European Journal of Preventive Cardiology, 2020, 27, 2292-2295.	1.8	2
42	Benefits and Risks of Prolonged Duration Dual Antiplatelet Therapy (Clopidogrel and Aspirin) After Percutaneous Coronary Intervention in High-Risk Patients With Diabetes Mellitus. American Journal of Cardiology, 2021, 142, 14-24.	1.6	2
43	Gender differences in treatment strategies among patients ≥80 years old with non-ST-segment elevation myocardial infarction. Journal of Thoracic Disease, 2019, 11, 5258-5265.	1.4	1
44	Mis-estimation of coronary lesions and rectification by SYNTAX score feedback for coronary revascularization appropriateness. Chinese Medical Journal, 2020, 133, 1276-1284.	2.3	1
45	Comparison of outcomes for percutaneous coronary intervention in men and women with unprotected left main disease. Journal of Geriatric Cardiology, 2021, 18, 168-174.	0.2	1
46	Effect of type 2 diabetes on coronary artery ectasia: smaller lesion diameter and shorter lesion length but similar adverse cardiovascular events. Cardiovascular Diabetology, 2022, 21, 9.	6.8	1
47	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity C-Reactive Protein in Patients With Previous Myocardial Infarction. Frontiers in Cardiovascular Medicine, 2022, 9, 797297.	2.4	1
48	Directly Measured vs. Calculated Low-Density Lipoprotein Cholesterol Does Not Identify Additional Individuals With Coronary Artery Disease and Diabetes at Higher Risk of Adverse Events: Insight From a Large Percutaneous Coronary Intervention Cohort in Asia. Frontiers in Cardiovascular Medicine, 0, 9,	2.4	1
49	Letter to the Editor: How Should We Treat High-risk Patients in the Chronic Phase Following PCI: Clopidogrel or Prolonged DAPT?. Journal of Korean Medical Science, 2021, 36, e167.	2.5	0
50	Longâ€ŧerm clinical outcomes in transradial versus transfemoral access for left main percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2021, 97, 1009-1015.	1.7	0
51	Cross‑sectional study of retroperitoneal hematoma after invasive intervention in a Chinese population: Prevalence, characteristics, management and outcomes. Experimental and Therapeutic Medicine, 2020, 20, 2975-2984.	1.8	0
52	Thrombotic vs. Bleeding Events of Interruption of Dual Antiplatelet Therapy within 12 Months among Patients with Stent-Driven High Ischemic Risk Definition following PCI. Journal of Interventional Cardiology, 2022, 2022, 1-15.	1.2	0
53	Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease. Frontiers in Endocrinology, 2022, 13, 860698.	3.5	0